GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (STU:0K4) » Definitions » Dividend-Payout-to-FFO

Akero Therapeutics (STU:0K4) Dividend-Payout-to-FFO


View and export this data going back to 2020. Start your Free Trial

What is Akero Therapeutics Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


Akero Therapeutics Business Description

Traded in Other Exchanges
Address
601 Gateway Boulevard, Suite 350, South San Francisco, CA, USA, 94080
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.